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Anti-cytokine therapy in fibrosing alveolitis: where are we now?
Ann Millar
University of Bristol Medical School, Bristol, UK
Abstract
Idiopathic pulmonary fibrosis (IPF) is a condition that has a poor prognosis, with a median
survival of 4–5 years irrespective of treatment. Ziesche et al (N Engl J Med 1999, 341:
1264–1269) describe an open randomised trial of 18 patients with IPF, unresponsive to
corticosteroid treatment at high dose. Nine patients were treated with continued
corticosteroid and nine with prednisolone plus interferon-g 1b (IFN-g). Significant benefits in
physiological parameters are reported in the IFN-g-treated group. An analysis of lung tissue
by reverse-transcriptase-mediated polymerase chain reaction showed corresponding
decreases in the transcription of transforming growth factor-b1 and connective tissue
growth factor. This is the first report of treatment showing efficacy in this disease, albeit in a
very preliminary study, but the data should be viewed with caution. This study is discussed in
the context of other published studies of treatment for IPF and the scientific rationale on
which it was based.
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Idiopathic pulmonary fibrosis (IPF) is a chronic debilitating
illness that leads inexorably to respiratory failure and death
in most patients [1]. The 5-year mortality approaches 50%
in most studies [2]. The efficacy of any treatment is ques-
tionable and this can lead to a rather nihilistic approach.
Received wisdom suggests that this is a rare disease
occurring mainly in elderly men and for which currently
available treatment is often ineffective and can induce side
effects that are worse than the condition itself. The symp-
toms of gradually increasing breathlessness are non-spe-
cific and often attributed to ‘old age’, leading to
presentation at a point that can be late in the natural
history of the condition. Current therapy is usually corti-
costeroids with or without some form of immunosuppres-
sant. However, the data upon which this is based are
limited. The fact that these treatments are still widely used
reflects the difficulty of a palliative approach for clinicians
and patients in such a distressing condition.
The available studies of treatment for IPF are in small
numbers of patients and are rarely controlled trials [3–14].
On reviewing these studies, it is apparent that some of the
patients had collagen vascular disease and therefore did
not have IPF. A significant number of the responders wereRespiratory Research    Vol 1 No 1 Millar
less than 50 years old and were female, which is atypical.
Histological data on these subjects were limited. The
recent reclassification of interstitial lung diseases by histo-
logical features has shown a clear association between
subtypes and response to treatment. Usual interstitial
pneumonia (UIP) is the histological pattern that identifies
IPF with little response to treatment [15,16]. Overall, these
data suggest that those patients who responded to treat-
ment in a previous trial might have had non-specific inter-
stitial pneumonia (NSIP) rather than UIP. This exemplifies
problems in the design and practice of appropriate trials in
IPF owing to the relative rarity of the disease, the difficul-
ties of including placebo controls, and the numbers of
patients required to detect objective improvements.
Treatment with corticosteroids and immunosuppresive
therapy is based on the concept that IPF is due to abnor-
malities in the immunoregulatory response, leading to pro-
gressive fibrosis rather than healing and resolution. These
therapies have not been targeted at fibrogenic factors.
There is a significant literature on the potential role of the
fibrogenic factors transforming growth factor-b (TGF-b)
and connective tissue growth factor (CTGF) in IPF
[17,18]. It has also been demonstrated in vitro that several
agents, including pirfenidone (5-methyl-1-phenyl-2-(1H)-
pyridone) and IFN-g, decreases their production [19,20].
The use of these agents in therapeutic trials in IPF is an
exciting prospect because potentially they are affecting
fibrogenesis, which can be considered a downstream
aspect in the pathogenesis of IPF, a common point for
clinical presentation.
One study has previously reported on the anti-fibrotic
agent pirfenidone in patients with IPF [21]. This showed
some limited improvement and was performed in patients
with advanced diseases. Ziesche et al [22] have reported
an open clinical trial of IFN-g in patients with IPF. Patients
were excluded if they had a total lung capacity [TLC] of
less than 45% of predicted and were regarded as end
stage. Patients were considered eligible if they showed no
response to corticosteroid at high dose (50 mg daily for
4 weeks), with response defined as an improvement in TLC
of 10%. Eighteen subjects were recruited, nine were
treated with prednisolone at low dose (7.5 mg/day) and
compared with nine treated with IFN-g (200 mg, three times
daily) and prednisolone (7.5 mg/week). Significant
changes were reported in the IFN-g-treated group after 12
months. Three physiological endpoints were described.
Total lung capacity had decreased by 4% in the control
group (from 66 ± 8% to 62 ± 6% of predicted) compared
with an increase of 9% in the IFN-g group (70 ± 10% to
79 ± 12% of predicted). The resting partial pressure of
arterial oxygen (PaO2) decreased in the control group from
65 ± 6 to 62 ± 4 mmHg compared with an increase in the
IFN-g group from 64 ± 9 to 76 ± 8 mmHg, with comparable
improvements in post-exercise PaO2. No data were
reported on cigarette smoking, which is known to have an
effect on outcome [23].
Transcriptional changes in TGF-b1 and CTGF, measured by
semiquantitative RT–PCR (reverse-transcriptase-mediated
polymerase chain reaction), were also demonstrated in the
IFN-g group. These data permit speculation on the mecha-
nisms responsible for these documented improvements.
These data are promising but must be treated with caution
[24]. The patients studied were identified by clinical, radi-
ographic (including high-resolution computed tomography),
physiological parameters and histological data. Fifteen had
undergone open lung biopsy and three had undergone
transbronchial biopsy; IPF was diagnosed on the basis of
the presence of subpleural and periacinar fibrotic lesions
with minor cellular infiltration. The recent histological reclas-
sification of IPF shows a very significant relationship
between subtype and both mortality and response to treat-
ment, as mentioned previously [15]. The data would be sig-
nificantly strengthened if the authors now had a histological
review by an independent pathological expert. In addition to
these histological criteria, the patients had to have shown a
deterioration of a minimum of 10% decrease in lung func-
tion in the preceding 12 months despite treatment with cor-
ticosteroid and/or immunosuppressive agents for at least 6
of the preceding 12 months. The patients had a mean age
of 61 years, which is young for this disease. At the start of
the study the mean values of TLC were 66 ± 6% and
70 ± 10% of predicted in the two groups, which is a level
that is rarely seen in the outpatient setting in the UK. An
increase of 10% or 200 ml in TLC is required for an
improvement to be considered significant. The authors have
replied to comments on this issue, pointing out that in view
of the relatively well preserved TLC in their subjects there
was a mean increase of approximately 50 ml in their sub-
jects [25]. The figures for gas transfer are not given, which
is an important physiological measure that is regarded by
some authorities as the most crucial in monitoring. PaO2
values before and after maximal exercise were used as sur-
rogate markers of gas exchange; however, no details of the
exercise performed are given, so corrections for work per-
formed cannot be made. Furthermore the 5-year mortality
for this disease is in the region of 50%, but there were no
deaths in the 18 patients despite a total of seven patients
requiring oxygen therapy. The patients described in this
study are unusual in their ‘physiological health’ at the entry
to the study and lack of deterioration in the course of the
study. This leads to a question of whether their apparent
response to IFN-g can be considered representative of IPF,
in particular of the UIP subset, by contrast with those with
the more responsive NSIP subset. Further studies of this
agent are warranted but the problem of patient selection for
studies of IPF remains unresolved: on the one hand, the
stricter the criteria the more difficult recruitment becomes;
on the other hand is the large number required to detect
significant clinical outcomes.c
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This study gives us a glimmer of hope, firstly to raise the
profile of IPF as a disease requiring more and very well
designed clinical trials, and secondly as the second study
to look at agents that are potentially antifibrotic, targeting
the process that leads to the disability of IPF.
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